Effect of core needle biopsy number on intraductal carcinoma of the prostate (IDC-P) diagnosis in patients with metastatic hormone-sensitive prostate cancer

Int J Clin Oncol. 2020 Dec;25(12):2130-2137. doi: 10.1007/s10147-020-01756-0. Epub 2020 Aug 3.

Abstract

Background: The number of core needle biopsies in metastatic prostate cancer cases are sometimes reduced to avoid various complications. We analyzed whether core needle biopsy number influence IDC-P detection rate in patients with metastatic castration-sensitive prostate cancer (mHSPC).

Methods: We retrospectively evaluated data from 150 patients diagnosed with mHSPC. Subjects were allocated to three groups according to the number of core biopsies performed: ≤ 5, 6-9, and ≥ 10. The study endpoints were the cancer-specific survival (CSS) and overall survival (OS) rates.

Results: For patients who underwent ≥ 10 core biopsies, a significant difference on CSS was detected between with or without IDC-P (P = 0.016). On the other hand, the difference decreased as the number of core biopsies became smaller (6-9; P = 0.322 and ≤ 5; P = 0.815). A similar trend was identified for the OS outcome. A significant difference on OS was also found between with or without IDC-P in patients who underwent ≥ 10 and 6-9 core needle biopsies (P = 0.0002 and 0.017, respectively), but not in those who underwent ≤ 5 core biopsies (P = 0.341). IDC-P served as a stronger prognostic marker for CSS and OS than did the other factors included in the multivariate analysis for patients had ≥ 10 core biopsies (P = 0.016, and P = 0.0014, respectively).

Conclusions: Given the IDC-P detection and its value as a prognostic marker, we propose the performance of ≥ 10 core biopsy procedures in patients diagnosed with mHSPC to minimize the sampling error of the IDC-P.

Keywords: Biopsy number; IDC-P; Prostate cancer; mHSPC.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biopsy, Large-Core Needle / methods*
  • Bone Neoplasms / secondary
  • Carcinoma, Ductal / mortality
  • Carcinoma, Ductal / pathology*
  • Hormones
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology*
  • Retrospective Studies

Substances

  • Hormones